Pliant Therapeutics PLRX 深 滬
已收盤 12-24 16:00:00 美东时间
1.23
+0.020
+1.65%
華盛通- 最 高1.24
- 今 開1.21
- 成交量 26.71万股
- 最 低 1.19
- 昨 收 1.21
- 總市值 7550.75万
- 52周最高 13.71
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 1.1001
- 委 比 63.93%
- 總股本 6138.82万
- 歷史最高 43.92
- 量 比 0.33
- 振 幅 4.13%
- 歷史最低 1.1001
- 每 手 1
- 風險率 3.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics posts interim Phase 1 data showing antitumor activity and durable responses for PLN-101095 in ICI-refractory advanced cancer patients.
12-05 02:53
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
Pliant Therapeutics Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2–4, 2025. Bernard Coulie, Keith Cummings, and Éric Lefebvre, senior executives of the company, will engage in a fireside chat on December 4 at 12:30 p.m. ET. The live webcast and replay can be accessed through the company's website. Pliant Therapeutics specializes in developing integrin-based therapies for treating solid tumors and musc...
12-01 13:30
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Pliant Therapeutics Q3 EPS $(0.43) Beats $(0.52) Estimate
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 54.74 percent increase over losses of $(0.95) per share
11-07 05:43
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Pliant Therapeutics provided a corporate update and reported third quarter 2025 financial results. The company advanced its oncology program with Phase 1 trial data expected by year-end 2025. Close out activities for the BEACON-IPF trial are set to complete in the fourth quarter. The company discontinued BEACON-IPF and reduced expenses, with a net loss of $26.3 million in Q3 2025. It held $243.3 million in cash as of September 2025.
11-06 21:05
Pliant Therapeutics Announces CBO Hans Hull’s Resignation
Pliant Therapeutics ( ($PLRX) ) just unveiled an announcement. On October 20, 2...
10-25 04:59
期权扫描 | 股价三日疯涨600%！Beyond Meat期权成交居全美第一，Call异动大单持续押注
股价三日疯涨600%！Beyond Meat期权成交达252万张居全美第一，获Call大单持续押注；亚马逊期权成交放量35万张，加速部署机器人替代人工>>
10-22 13:39
Pliant Therapeutics Settles Loan with Oxford Finance
Pliant Therapeutics ( ($PLRX) ) has provided an announcement. On October 14, 20...
10-21 06:11
Allogene licensor Cellectis faces patent lawsuit in the U.S.
Cancer drug developer Allogene Therapeutics (NASDAQ:ALLO) announced on Tuesday that its licensor, Cellectis (NASDAQ:CLLS), is facing a lawsuit in the U.S. over allegations of patent infringement relat...
10-14 22:25
